Carbon-ion radiotherapy for marginal lymph node recurrences of cervical cancer after definitive radiotherapy: a case report

Radiation Oncology

Takashi Nakano³  Tadashi Kamada²  Shingo Kato¹  Masaru Wakatsuki²  Ken Ando³  Yu Ohkubo³  Shin-ei Noda³  Hiroki Kiyohara³  Tatsuya Ohno³  Tomoaki Tamaki³ 

[1]Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka-shi, Saitama, 350-1298, Japan

[2]Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba, 263-8555, Japan

[3]Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi-shi, Gunma, 371-8511, Japan

关键词: Cervical cancers;    Marginal recurrences;    Carbon-ion radiotherapy;   

Others  :  1154260
DOI  :  10.1186/1748-717X-8-79

 received in 2013-01-23, accepted in 2013-04-01,  发布年份 2013

【 摘 要 】

Recurrences of cervical cancer after definitive radiotherapy often occur at common iliac or para-aortic lymph nodes as marginal lymph node recurrences. Patients with these recurrences have a chance of long-term survival by optimal re-treatment with radiotherapy. However, the re-irradiation often overlaps the initial and the secondary radiotherapy fields and can result in increased normal tissue toxicities in the bowels or the stomach. Carbon-ion radiotherapy, a form of particle beam radiotherapy using accelerated carbon ions, offers more conformal and sharp dose distribution than X-ray radiotherapy. Therefore, this approach enables the delivery of high radiation doses to the target while sparing its surrounding normal tissues. Marginal lymph node recurrences in common iliac lymph nodes after radiotherapy were treated successfully by carbon-ion radiotherapy in two patients. These two patients were initially treated with a combination of external beam radiotherapy and intracavitary and interstitial brachytherapy. However, the diseases recurred in the lymph nodes near the border of the initial radiotherapy fields after 22 months and 23 months. Because re-irradiation with X-ray radiotherapy may deliver high doses to a section of the bowels, carbon-ion radiotherapy was selected to treat the lymph node recurrences. A total dose of 48 Gy (RBE) in 12 fractions over 3 weeks was given to the lymph node recurrences, and the tumors disappeared completely with no severe acute toxicities. The two patients showed no evidence of disease for 75 months and 63 months after the initial radiotherapy and for 50 months and 37 months after the carbon-ion radiotherapy, respectively. No severe late adverse effects are observed in these patients. The two presented cases suggest that the highly conformal dose distribution of carbon-ion radiotherapy may be beneficial in the treatment of marginal lymph node recurrences after radiotherapy. In addition, the higher biological effect of carbon-ion radiotherapy and its superior dose distribution may provide more effective tumor control in treatment for re-irradiation of the marginal recurrences in radiation resistant tumors other than cervical cancer.

【 授权许可】

   
2013 Tamaki et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Beadle BM, Jhingran A, Yom SS, Ramirez PT, Eifel PJ: Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2010, 76:1396-1403.
• [2]Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C, Kataoka M, Suzuki K, Ii N, Uno T, Takanaka T, Higuchi K, Yamazaki H, Tokumaru S, Oguchi M, Hayakawa K: Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. Int J Radiat Oncol Biol Phys 2006, 66:1366-1369.
• [3]Schulz-Ertner D, Tsujii H: Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007, 25:953-964.
• [4]Tsujii H, Kamada T: A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol 2012, 42:670-685.
• [5]Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol 2004, 22:872-880.
• [6]Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K, Cervical Cancer (Vulva Cancer) Committee of Japanese Gynecologic Oncology Group (JGOG): Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol 2012, 126:211-216.
• [7]Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, Miften M: Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010, 76(Suppl 3):101-107.
• [8]Nakano T, Suzuki Y, Ohno T, Kato S, Suzuki M, Morita S, Sato S, Oka K, Tsujii H: Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin Cancer Res 2006, 12:2185-2190.